Decapeptid effect in myoma

A Randomized controlled clinical trial comparing the effects of aromataseinhibitor(letrozole)and gonadotropin-releasing hormone(triptoreline) on uterine leiomyoma volum

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201012045307N1

Enrollment

Registered

2011-10-26

Start date

2011-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myoma. Myoma

Interventions

Tab.Letrozol 2.5 mg at day of mens Amp.Triptorelin3.75 mg evry month(3month).

Treatment - Drugs

Tab.Letrozol 2.5 mg at day of mens Amp.Triptorelin3.75 mg evry month(3month)

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Included:Age between 18 to50 years old; myoma size equal or more than 5cm with abnormal vaginal bleeding, unexplained inferility, pelvic pain, dysmenorrea and signs related to mass. Exclusion criteria: Multiple myoma size more than 2cm and hormonal therapy during last month major disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Uterus myoma size. Timepoint: Baseline, weeks 2, 4, 6 and 12. Method of measurement: Myoma size with transvaginal sonography(cm).	—

Secondary

Measure	Time frame
Dysuria. Timepoint: Weeks 2, 4, 6 and 12. Method of measurement: Questionnaire.;Flushing. Timepoint: Weeks 2, 4, 6 and 12. Method of measurement: Questionnaire.;Dryness of vagina. Timepoint: Weeks 2, 4, 6 and 12. Method of measurement: Questionnaire.;Dysparunia. Timepoint: Weeks 2, 4, 6 and 12. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Soghra Rabiee

Hamedan University of Medical Sciences

rabieesogol@yahoo.com+98 81 1827 7012

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026